Ethan Dmitrovsky
Papers
2
Total Citations
116
H-Index
2
About
Ethan Dmitrovsky is a pioneering cancer researcher whose work has fundamentally reshaped our understanding of cell cycle regulation in lung cancer. His research centers on cyclin-dependent kinases (CDKs) and their role in tumorigenesis, with a particular focus on exploiting these pathways for targeted therapy. Dmitrovsky’s major contribution lies in elucidating the concept of “anaphase catastrophe”—a novel mechanism of cell death triggered by CDK inhibition in cancer cells with supernumerary centrosomes. His landmark 2009 study demonstrated that targeting the cyclin E-CDK2 complex not only suppresses lung cancer growth but does so through this previously unrecognized mitotic vulnerability, garnering 67 citations. He further advanced the field by evaluating next-generation CDK2/9 inhibitors, such as CCT68127, showing their enhanced potency in inducing anaphase catastrophe and apoptosis. With over 49 citations for his 2016 work, Dmitrovsky’s research has provided a mechanistic foundation for developing more selective CDK inhibitors, offering new therapeutic strategies for patients with lung cancer and other malignancies characterized by centrosome amplification.
Research Focus
Key Achievements
Top Papers
- 1
- 2Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016